Celldex Therapeutics, Inc. is 1.3x more valuable than Intellia Therapeutics, Inc. by market capitalization ($2.30 B vs $1.73 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CLDX | NTLA |
|---|---|---|
| Market cap | $2.30 B | $1.73 B |
| US-listed rank | #1997 | #2213 |
| Revenue (latest FY) | $1.54M | $67.67M |
| Net income (latest FY) | -$258.76M | -$412.69M |
| Net margin | -16748.0% | -609.9% |
| SEC filings | 1,268 | 687 |
Celldex Therapeutics, Inc. is 1.3x more valuable than Intellia Therapeutics, Inc. by market capitalization ($2.30 B vs $1.73 B).
In their latest fiscal years, Celldex Therapeutics, Inc. reported $1.54M in revenue while Intellia Therapeutics, Inc. reported $67.67M.
Full pages: Celldex Therapeutics, Inc. and Intellia Therapeutics, Inc., or browse the full rankings.